- Conditions
- Autism Spectrum Disorder
- Interventions
- Minocycline
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 35 Years · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 598
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Clear Cell Renal Cell Carcinoma
- Interventions
- PD-32766D (a Copper-64 [64Cu] labeled peptide), PD-32766T (an Actinium-225 [225Ac] labeled peptide)
- Drug
- Lead sponsor
- PeptiDream Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Alzheimer Disease
- Interventions
- F 18 T807
- Drug
- Lead sponsor
- Tammie L. S. Benzinger, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Healthy, Alzheimer Disease
- Interventions
- [F18]RO-948, [F18]MK-6240, [F18]AV1451
- Diagnostic Test
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 50 Years to 100 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Healthy Volunteers
- Interventions
- TAK-915
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Lobular Carcinoma, Metastatic Breast Lobular Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
- Interventions
- Computed Tomography, Fluciclovine F18, Gallium Ga 68 Gozetotide, Positron Emission Tomography
- Procedure · Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Carotid Artery Disease, Carotid Stenosis
- Interventions
- [F-18] RDG-K5
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Hormone Refractory Prostate Cancer
- Interventions
- IV fluorine-18 labeled methylcholine before PET/CT
- Drug
- Lead sponsor
- Queen's Medical Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Honolulu, Hawaii
- Conditions
- Sickle Cell Disease
- Interventions
- [13N]NH3, Lexiscan, Positron emission tomography
- Drug · Diagnostic Test
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 18 Years to 21 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Interventions
- F-18 16 alpha-fluoroestradiol, fludeoxyglucose F 18, positron emission tomography, computed tomography, laboratory biomarker analysis
- Radiation · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Posterior Cortical Atrophy
- Interventions
- HD-tDCS sessions, Sham HD-tDCS sessions, HD-tDCS sessions - Open-label (after randomized treatment)
- Device
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma
- Interventions
- Copper Cu 64 PSMA I&T
- Drug
- Lead sponsor
- Curium US LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 439 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 43
- States / cities
- Homewood, Alabama • Little Rock, Arkansas • Fullerton, California + 35 more
- Conditions
- ccRCC, Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), Renal Cell Cancer Metastatic, Renal Cell Cancer, Recurrent, Clear Cell Renal Cell Cancer (ccRCC)
- Interventions
- 177Lu-TLX250
- Drug
- Lead sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 8
- States / cities
- Duarte, California • San Diego, California • Miami, Florida + 5 more
- Conditions
- Metastatic Melanoma
- Interventions
- Bempegaldesleukin (NKTR-214), Nivolumab, ⁸⁹Zr-Df-IAB22M2C
- Biological · Drug
- Lead sponsor
- Nektar Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 3
- States / cities
- Duarte, California • Portland, Oregon • Philadelphia, Pennsylvania
- Conditions
- Solid Tumors, Adult, Metastatic Cancer
- Interventions
- Gallium-68 labelled (68Ga-) FAP-2286, Positron Emission Tomography (PET) imaging, Copper-64 labeled (64Cu-) FAP-2286
- Drug · Procedure
- Lead sponsor
- Thomas Hope
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 191 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Gallium Ga 68 Gozetotide, Hepatic Artery Embolization, Positron Emission Tomography and Computed Tomography Scan
- Radiation · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Esophageal Cancer
- Interventions
- Radiation, FMISO PET CT
- Radiation · Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Soft Tissue Sarcoma
- Interventions
- 18F-FMISO
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Cardiomyopathies, Primary
- Interventions
- (18F)Flutemetamol
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Apalutamide, Computed Tomography, Degarelix, External Beam Radiation Therapy, Fluciclovine F18, Goserelin Acetate, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Leuprolide Acetate, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Relugolix, Stereotactic Body Radiation Therapy, Triptorelin, Volume Modulated Arc Therapy
- Radiation · Drug · Procedure + 1 more
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 804 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2032
- U.S. locations
- 341
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 240 more
- Conditions
- Alzheimer Disease, Cognitive Impairment, Cognitive Decline
- Interventions
- Amyloid PET scan, Tau PET scan using MK-6240, Neurocognitive testing, MRI
- Radiation · Drug · Behavioral + 1 more
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Irvine, California
- Conditions
- Parkinson's Disease, Primary Parkinsonism, Lewy Body Parkinson's Disease
- Interventions
- 18F-AV-133
- Drug
- Lead sponsor
- Avid Radiopharmaceuticals
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 14
- States / cities
- Scottsdale, Arizona • Sun City, Arizona • New Haven, Connecticut + 11 more
- Conditions
- Ventricular Tachycardia, Arrhythmia
- Interventions
- 123I-metaiodobenzylguanidine
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2019
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Grade 3b Follicular Lymphoma, Refractory Primary Mediastinal Large B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
- Interventions
- Cyclophosphamide, Fludarabine, Lisocabtagene Maraleucel, Polymer-conjugated IL-15 Receptor Agonist NKTR-255, X-Ray Imaging, Echocardiography, Multigated Acquisition Scan, Bone Marrow Biopsy, Bone Marrow Aspiration, Lumbar Puncture, Computed Tomography, Positron Emission Tomography, Biospecimen Collection, Biopsy
- Drug · Biological · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Seattle, Washington